2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1962

Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target
Abstract Number: 1963

Thrombospondin-1 Is Elevated in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Free Active TGF-b1 Levels, IL-1b and IL-17A
Abstract Number: 1964

The Frequency and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with and without Lupus
Abstract Number: 1965

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up
Abstract Number: 1966

Antibodies Against Domain 1 and Domain 4/5 of β2 Glycoprotein I: Clinical Relevance in Obstetric Anti-Phospholipid Syndrome
Abstract Number: 1967

Depression Is a Risk Factor for Low Treatment Adherence in African American People with Systemic Lupus Erythematosus
Abstract Number: 1968

Adverse Childhood Experiences and Outcomes of Systemic Lupus Erythematosus
Abstract Number: 1969

Peer Approaches to Lupus Self-Management (PALS): A Novel Lupus Peer Mentorship Intervention
Abstract Number: 1970

Disparities in Access to Specialist Care at the Time of Diagnosis of Systemic Lupus Erythematosus
Abstract Number: 1971

Predictors of Delays to Care and Associated Outcomes in Pediatric Lupus Patients from the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1972

Creatine Kinase in the United States Population: Impact of Demographics, Comorbidities and Body Composition on the Normal Range
Abstract Number: 1973

Intramuscular Versus Ultrasound Guided Peritendinous Glucocorticoid Injection for Tenosynovitis in Patients with Rheumatoid Arthritis – a Randomised, Double-Blind, Controlled Study
Abstract Number: 1974

Is Ultrasound of the Hands Enough to Reveal Ongoing Subclinical Inflammation in Rheumatoid Arthritis Patients in Clinical Remission According to Composite Scores?
Abstract Number: 1975

Severity and Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis
Abstract Number: 1976

Ultrasound Inflammation in Patients Presenting with Arthralgia Is Associated with Developing Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].